Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elliot Stieglitz

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
JCO Precision Oncology|November 9, 2023
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity AssayElliot Stieglitz, Christine J Gu, Michelle Richardson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2022
Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cellsBaskar Ramdas, Lisa Deng Yuen, Lakshmi Reddy Palam, et al.
Cancer Discovery|June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology GroupElliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Leukemia|September 13, 2019
Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencingAlexander K Chao, Julia A Meyer, Alex G Lee, et al.
Pediatric Blood & Cancer|February 24, 2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology GroupElliot Stieglitz, Ashley F Ward, Robert B Gerbing, et al.
Bone Marrow Transplantation|May 12, 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantVanessa A Fabrizio, Nancy A Kernan, Farid Boulad, et al.
Journal for Immunotherapy of Cancer|November 25, 2023
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesWilliam C Temple, Matthew A Nix, Akul Naik, et al.
Blood Advances|September 28, 2021
Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemiaHironobu Kitazawa, Yusuke Okuno, Hideki Muramatsu, et al.
Leukemia|September 13, 2018
Downregulating Notch counteracts KrasGuangyao Kong, Xiaona You, Zhi Wen, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
JCO Precision Oncology|November 9, 2023
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity AssayElliot Stieglitz, Christine J Gu, Michelle Richardson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2022
Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cellsBaskar Ramdas, Lisa Deng Yuen, Lakshmi Reddy Palam, et al.
Cancer Discovery|June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology GroupElliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Leukemia|September 13, 2019
Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencingAlexander K Chao, Julia A Meyer, Alex G Lee, et al.
Pediatric Blood & Cancer|February 24, 2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology GroupElliot Stieglitz, Ashley F Ward, Robert B Gerbing, et al.
Bone Marrow Transplantation|May 12, 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantVanessa A Fabrizio, Nancy A Kernan, Farid Boulad, et al.
Journal for Immunotherapy of Cancer|November 25, 2023
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesWilliam C Temple, Matthew A Nix, Akul Naik, et al.
Blood Advances|September 28, 2021
Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemiaHironobu Kitazawa, Yusuke Okuno, Hideki Muramatsu, et al.
Leukemia|September 13, 2018
Downregulating Notch counteracts KrasGuangyao Kong, Xiaona You, Zhi Wen, et al.
Pageof 9